NervGen Pharma Corp.

Contributing Author

Recent Articles by NervGen Pharma Corp.

Mar-12	NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange NGEN GlobeNewswire
Mar-04	NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs NGEN +8.10% GlobeNewswire
Feb-18	NervGen Pharma to Participate at Upcoming Investor Conferences NGEN GlobeNewswire
Feb-12	NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams NGEN GlobeNewswire
Feb-11	NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium NGEN GlobeNewswire
Feb-09	NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury NGEN GlobeNewswire
Jan-20	NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing NGEN -6.93% GlobeNewswire
Jan-08	NervGen Pharma Begins Trading on Nasdaq Today NGEN GlobeNewswire